Myotonic dystrophy type one causes dysregulation of drug metabolism and fatty accumulation in the liver
Year: 2024
Type: article
Abstract: Myotonic Dystrophy type 1 (DM1) is a multi-systemic muscular dystrophy affecting 1 in 3000 people, characterized by muscle wasting, myotonia, cognitive impairment, and cardiac and gastrointestinal abnormalities, among other symptoms.DM1 results from a (CTG)n repeat expansion in the 3' UTR of the ubiquitously expressed gene DMPK.The (CUG)n-containing RNAs resulting from the transcription of this diseased DMPK gene aggregate in the nucleus, forming foci that sequester muscleblind-like (MBNL) family proteins, important splicing factors with roles in the developmental transition from juveniles to adults in many tissues.In addition to muscle pathologies, DM1 patients exhibit increased susceptibility toward glucose intolerance, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome.Furthermore, DM1 patients exhibit heightened sensitivity to a wide range of analgesics and anesthetics, leading to complications ranging from prolonged anesthesia recovery to heightened pulmonary dysfunction.These findings suggest a predisposition for liver damage and dysfunction in DM1 patients, but this possibility has remained unexplored.To investigate the impact of DM1 in the liver, we generated a DM1 mouse model in which we can induce the expression of CUG-containing RNA, specifically in the liver.Through these mice, we demonstrate that the expression of the toxic CUG RNA sequesters MBNL proteins in the hepatocytes, causing a reduction in mature hepatocellular activity.However, unlike other tissues, loss of MBNL1 activity only reproduces a small portion of the transcriptome changes in DM1-afflicted hepatocytes.We characterized the transcriptomic changes driven by DM1 in the liver and showed that these lead to changes in hepatocellular morphology, inflammation, necrosis, and excessive lipid accumulation.Furthermore, we find that DM1 mice livers are defective in drug metabolism and clearance and, when challenged, exhibit an impaired response to zoxazolamine-induced paralysis and acetaminophen-induced hepatotoxicity.Finally, we observe that DM1 sensitizes the liver to diet-induced NAFLD, increasing the likelihood of NAFLD development in patients who consume high-fat, high-sugar diets.Our data suggests this
Author: Dewald, Zachary L.
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Keywords: myotonic dystrophy type 1, CUG repeat expansion, DMPK, MBNL1, MBNL2, RNA sequestration, hepatocytes, drug metabolism, hepatic steatosis, non-alcoholic fatty liver disease, acetaminophen hepatotoxicity, liver transcriptome, hepatocyte inflammation, liver necrosis, high-fat high-sugar diet, mouse model
Open Access status: green
OpenAlex ID: W7220777475
